Articles tagged with Cancer Patients
Researchers developed a mathematical technique to measure total tumor-specific mRNA levels from bulk tumor sequencing data, associating higher mRNA levels with reduced patient survival. The study suggests this approach could serve as a prognostic biomarker for various cancers, guiding treatment selection.
A novel targeted radionuclide alpha therapy, AC-NM600, has been shown to achieve significantly better outcomes than its corresponding beta therapy in treating metastatic castration-resistant prostate cancer. The study demonstrated slowed tumor growth and improved overall survival.
Researchers at the University of Cincinnati are studying how lipids help fortify lung cancer cells and if targeting them can lead to better outcomes. The team discovered that lipids play a crucial role in cancer cell growth, membrane fortification, and energy production.
A recent Oregon State University study found that a mindfulness-based intervention delivered via videoconference was a feasible treatment option for survivors of breast and gynecologic cancers. The pilot study showed that participants learned mindfulness exercises, gained insight into sexual interest, and appreciated the group's suppor...
A phase 3 randomized study showed that momelotinib significantly improved outcomes for patients with myelofibrosis, a rare and fatal bone marrow cancer. The oral pill met all primary and secondary endpoints, showing a trend toward overall survival benefit within six months.
A new study found significant racial disparities in receiving immunotherapy for advanced liver cancer, with Black and Hispanic patients having lower access to the treatment. The analysis showed that immunotherapy was more effective than chemotherapy in improving survival rates.
Researchers found that a bridge therapy approach prior to consolidation therapy can improve event-free survival in patients with stable metastatic cancer after induction therapy. Patients who received this treatment had significantly better outcomes compared to those who underwent direct consolidation or post-induction therapy alone.
A multi-state study found that patients with advanced cancer who reported symptoms weekly using an electronic survey had better physical function and symptom control compared to those evaluated less frequently. The study showed a 35% better ability to function physically, a 16.1% better control of symptoms, and a 41% better overall hea...
A Phase 3 clinical trial is investigating the effectiveness of a combination of two immunotherapy drugs, nemvaluekin alfa and pembrolizumab, compared to standard chemotherapy for patients with platinum-resistant ovarian cancer. The trial aims to provide a novel treatment option with better efficacy and safety profiles.
A new study found that circulating tumor DNA can identify stage II colon cancer patients who benefit from chemotherapy, sparing others the need for treatment. The study showed reduced use of chemotherapy without compromising survival rates.
A study of patients with high-risk renal cell carcinoma found that those taking everolimus daily after surgery lived longer without disease recurrence. The results, although narrowly missed statistical significance, showed improvement primarily in very high-risk disease, with a 21% improvement in RFS for those with the highest risk.
Researchers analyzed 2,049 breast cancer samples to compare genomic alterations across younger and older age groups. Younger patients had higher rates of BRCA1 mutations and lower rates of CDH1 and PIK3CA mutations.
A new drug combination of ramucirumab and pembrolizumab significantly extended overall survival in advanced non-small cell lung cancer patients who had progressed on prior immunotherapy. The study found a 31% reduction in risk of death compared to standard therapy, with median overall survival times of 14.5 months.
A systematic review of 155 head and neck cancer clinical trials from 2010 to 2020 revealed that only 57% of studies reported race or ethnicity. Black and Asian or Pacific Islander patients were disproportionately underrepresented in these trials, highlighting a significant issue in the field.
Researchers validated a liquid biopsy test as a better predictor of immunotherapy response in lung cancer patients compared to traditional tumor biopsies. The test measures the PD-L1 biomarker in blood, showing improved accuracy in predicting treatment outcomes and survival.
A study by Cedars-Sinai researchers confirms that counting metastatic lymph nodes is a dominant predictor of cancer death, improving staging and treatment for solid tumors. The simple process can be applied in virtually all medical settings without increased cost or complexity.
Researchers have identified new biomarkers to detect non-small cell lung cancer in its early stages through a blood test, offering improved survival chances. The approach can also identify potential drug resistance, allowing clinicians to choose alternative treatment options.
A new study finds that cancer patients are at a greater risk of developing diabetes, particularly those with lung, pancreatic, breast, brain, urinary tract, or uterine cancers. The study also shows that cancer patients who develop diabetes die sooner than survivors without diabetes.
Researchers at the University of Chicago's Pritzker School of Molecular Engineering have developed a version of interleukin-12 that is activated only when it reaches a tumor, reducing side effects. The new 'masked' molecule has shown promising results in eliminating cancer cells and outperforming existing immune therapies.
A new large-scale study led by the American Cancer Society shows a decline in suicide risk among cancer patients in the US over the past two decades. However, this risk remains significantly higher than in the general population, with certain factors such as age, race, and socioeconomic status contributing to the increased risk.
Researchers have identified a previously unrecognized form of hormone therapy-resistant prostate cancer and found promising drug targets to treat it. The discovery opens the door to developing therapies that specifically target this disease, which accounts for approximately a quarter of castration-resistant prostate cancers.
The ECOG-ACRIN Cancer Research Group presented promising trial results at ASCO 2022, including an 8-year survival rate in the CHAARTED prostate trial. The research also explored outcomes by tobacco use in head and neck studies, shedding light on cancer treatment effectiveness.
A new interactive web portal, SpUR, catalogues over 1,000 splicing events found in cancers, highlighting their role in tumor development and progression. The database provides a platform for researchers to study RNA dysregulations in cancer and develop RNA-based anti-cancer drugs.
MD Anderson research highlights new treatments for skin cancers, including novel therapies. The institution also showcased improved goals of care programs, which demonstrated significant reductions in ICU mortality and improved patient outcomes during the COVID-19 pandemic.
Kaiser Permanente researchers present 10 studies on improving cancer care delivery, including strategies to reduce hospitalizations and mortality among older patients. The studies also explore the use of real-world data versus clinical trials in cancer treatment.
Research suggests that NF-κB over-activation is associated with improved outcomes in patients with HPV-positive head and neck cancer. An RNA-based classifier trained on tumors with specific mutations may improve prognostic classification, aiding in treatment personalization.
Research found that hypomethylating agents (HMAs) activated the oncofetal protein SALL4 in up to 40% of patients with MDS, resulting in poor patient survival. This activation is linked to demethylation and upregulation of oncogenes, suggesting a need for additional combination therapy.
A landmark trial found that a widely used diabetes drug, metformin, is not effective against the most common forms of early-stage breast cancer. However, researchers discovered a potential benefit for individuals with HER2-positive breast cancer, which accounts for about 20% of all breast cancers.
The Sheri and Les Biller Family Foundation has donated $10 million to City of Hope to expand its supportive care programs for cancer patients, improving treatment outcomes and quality of life. The partnership aims to establish supportive care as a standard practice in cancer care across the US.
A new study found that crown-like structures surrounding breast tumors in overweight and obese patients can hinder their response to therapy. Researchers identified a potential molecular biomarker, CD32B, which is associated with poorer treatment outcomes.
A recent study found that nearly one-quarter of young sarcoma patients continue to use opioids after treatment is completed. The researchers highlight the need for monitoring and age-appropriate strategies to manage pain while minimizing opioid exposure.
A population-scale study found COVID-19 vaccination is effective in most cancer patients but offers lower protection and wanes quickly. Vaccine effectiveness was lower (65.5%) in cancer patients compared to the general population (69.8%), with higher hospitalization and death risks despite vaccination.
A new study found that patient-reported physical well-being is a significant factor in determining cancer prognosis and survival. The research highlights the importance of shared decision-making in cancer treatment, suggesting that clinicians should prioritize listening to patients' perspectives.
A new study applies 'Deep Visual Proteomics' to cancer cells, revealing mechanisms driving tumor development and exposing therapeutic targets. The method integrates advances from four technologies to analyze protein landscapes, providing insights into cancer vulnerabilities.
A study found that patients with IgD multiple myeloma have a worse prognosis than other types, with higher mortality rates and more kidney damage. The rare blood cancer produces excessive light chains that can damage the kidneys if left untreated.
Cancer death rates among Black people decreased steadily between 1999 and 2019, yet they remained significantly higher compared to other racial and ethnic groups. The study highlights the need for improved access to cancer screening, earlier detection, and quality care, as systemic barriers contribute to disparities in cancer outcomes.
A nationwide study of 100 million hospitalizations found that percutaneous coronary intervention is safe and increasing among cancer patients. The study suggests that PCI can nearly double from 2016 to 2018 among patients with thrombocytopenia, without significantly increasing mortality.
Researchers identified two novel biomarkers that predict response to immunotherapy and adverse events in liver cancer patients. The study's findings enable more effective and individualized treatment of primary liver cancer hepatocellular carcinoma (HCC) patients, with fewer side effects.
A new study has found that robotic surgery reduces the chance of readmission by half and reveals a four-fold reduction in blood clots compared to open surgery. Patients also experience increased physical activity, stamina, and quality of life.
A new study reveals massive variations in hospice medication prescriptions, with treatment agency being the primary factor. Patients in agencies with high prescription rates were up to 50 times more likely to receive benzodiazepines or antipsychotics.
Research by University of Texas M.D. Anderson Cancer Center reveals adolescent and young adult leukemia survivors have shorter life spans than those without cancer. The study found inferior long-term mortality outcomes persist even decades after treatment, impacting quality of life and overall survival.
A study published by Mayo Clinic Cancer Center investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with CAR-T cell therapy. The team found that a gene called TIGIT drives CAR-T cell exhaustion and dysfunction, suggesting its blocking strategy may improve treatment efficacy.
A significant proportion of patients with head and neck squamous cell carcinoma who smoke daily at diagnosis continue to smoke two years post-treatment. Most quitters stop smoking within the first six months after treatment.
The new center aims to advance a groundbreaking combination of focused ultrasound and cancer immunotherapy, potentially revolutionizing cancer treatment. The partnership will focus on overcoming existing limitations of immunotherapy and expanding treatment options for various types of cancer.
A new study published in the Journal of the National Comprehensive Cancer Network (JNCCN) found that incorporating the Electronic Health Record-Enabled Evidence-Based Smoking Cessation Treatment (ELEVATE) program into electronic health records can significantly improve smoking cessation rates among cancer patients. The research demonst...
A new smoking-cessation program that targets cancer patients has been shown to increase the percentage of patients receiving treatment from 2% to nearly 30%, as well as improve quit rates. The program's costs are also lower than previous methods, averaging $70 per patient.
The new ASTRO guideline provides guidance on radiation therapy for brain metastases, including evidence-based recommendations for multidisciplinary planning and delivery of advanced techniques to manage intact and resected brain tumors. The guideline aims to improve quality of life and outcomes for patients with brain metastases.
A new study by Weill Cornell Medicine investigators found that T cells' genetic program and developmental path affect their response to immunotherapy. The results suggest that infiltrating T cells don't all meet the same fate in every tumor, with long-lived memory programs correlating strongly with overall survival
A systematic review and meta-analysis of 81 studies found that COVID-19 patients with cancer had a higher risk of death compared to those without cancer. Younger age, lung, and hematologic cancers were identified as risk factors for poor outcomes from COVID-19
Researchers at Ochsner Health and MD Anderson have discovered that blocking interleukin-6 (IL-6) in lab models improves cancer responses while minimizing inflammation in healthy tissue. By targeting this cytokine, immune checkpoint inhibitors may become more targeted on tumors with fewer side effects.
Cancer incidence is projected to double in SSA by 2040, with 1.4 million cases per year expected without rapid interventions. Women are more affected by cancer than men in the region, with breast and cervical cancers among the most common types.
CHOP researchers developed CancerVar, an artificial intelligence-empowered platform for interpreting somatic cancer mutations. The tool provides standardized procedures for assessing the clinical impacts of over 13 million somatic cancer mutations.
A recent study in JAMA Otolaryngology–Head & Neck Surgery reveals that thyroid cancer patients in the US experience substantial financial burdens. The researchers propose a novel framework to help guide future research and inform cancer care providers on cost considerations.
A new study uses artificial intelligence to predict bone fractures in cancer patients by creating a digital twin of the vertebra. The AI-assisted framework, ReconGAN, simulates how tumors affect the spine and predicts fracture risks, offering medical experts better treatment strategies and patient decisions.
Researchers developed a droplet-based microfluidic technology to produce micro-organospheres from cancer patient biopsies within an hour. These miniature tumors retain the original microenvironment and can be used for testing many drug conditions, showing almost perfect correlation with actual clinical treatment outcomes.
A new study led by UTHealth Houston found that patients with recent cancer diagnoses had a higher risk of death and hospitalization, but those with cancer more than one year ago were not significantly associated with increased mortality. The research also confirmed racial disparities in COVID-19 outcomes among cancer patients.
Researchers created patient-derived models of brain metastases that recapitulate human disseminated disease, reflecting clinical manifestations and biological characteristics. These models can be used to test therapeutic value of different treatments and explore new approaches tailored to each patient.
A study by University of Colorado Cancer Center member Jennifer Raybin found that creative arts therapy significantly improves quality of life for children and adolescents with cancer. The therapy, conducted by a trained clinician, helps patients express and process emotions through activities like dance, yoga, and art-making.
The S1216 study showed an unprecedented median OS of 70 months in the control arm, outperforming previous results by 24 months. This extended survival was attributed to additional life-prolonging treatments patients received after completing the trial therapy.
Researchers found that genetic mutations in the MAPK pathway, key to normal cell growth, can also make head and neck cancer vulnerable. Individualized genomic analysis can identify specific mutations and target drugs, offering a promising approach to precision medicine.